Company news
Argent Biopharma Ltd (ASX:RGT) news
Every Argent Biopharma Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Appendix 4E and 2026 Annual Report
August 31, 2026
FDA-CVM Establish INAD File for CannEpil Veterinary Program
August 25, 2026
US Veterinary Development Programme for CannEpil Commences
August 5, 2026
CannEpil Global Licence Expands into Veterinary Healthcare
July 30, 2026
RGT Executes Global CannEpil Licensing Deal for US$5.5M
July 6, 2026
Half Yearly Report and Accounts
February 27, 2026
Provisional Patent Lodged with USPTO for NanoBodies Platform
February 24, 2026
CannEpil - Largest Commercial Shipment Arrives in Ireland
February 22, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Streamlined Acquisition of AusCann Assets
January 13, 2026
A$11m Financing Facility to Complete Strategic Acquisition
November 16, 2025
Argent BioPharma : Quarterly Activities/Appendix 4C Cash Flow Report
October 31, 2025
Appendix 4E and 2025 Annual Report
August 29, 2025
Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
August 27, 2025
U.S. In Vivo Study Supports ArtemiC Efficacy
August 24, 2025
RGT Signs Binding Term Sheet to Acquire AusCann Assets
August 18, 2025
EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia
July 7, 2025
Argent BioPharma Enters Germany - Europe's Largest Market
April 23, 2025
Argent BioPharma : Strategic Agreement to Enhance Cannabinoid Development
April 14, 2025
Strategic Collaboration Agreement for Malta Facility
April 8, 2025
CannEpil Receives Approval for Prescription in Germany
April 2, 2025
CimetrA Phase IIb Clinical Trial Results
March 16, 2025
Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
March 16, 2025
Argent BioPharma : Exclusive Agreement for Malta Manufacturing Facility
March 11, 2025
Strategic Manufacturing Partnership with ECCPharm Limited
March 4, 2025
Half Year Accounts
February 28, 2025
Argent BioPharma : Corporate Update - Board Change
February 4, 2025
Placing to Raise US$4,500,000
January 6, 2025
Trading Halt
January 2, 2025
ASX Listing Update
November 28, 2024
Placing to Raise A$200,000
October 23, 2024
Preliminary Final Report
August 30, 2024
Voluntary Delisting from ASX
August 15, 2024
Placing to Raise US$2,000,000
July 15, 2024
Placing to Raise US$500,000
July 1, 2024
Company Update & Capital Raising
December 21, 2023
Retraction of Statement
December 20, 2023
Pause in trading
December 20, 2023
Share Purchase Plan Closed
August 29, 2023
Pre-clinical Trial Results on CimetrA
August 14, 2023
MGC Pharma Launches Share Purchase Plan
August 1, 2023
MGC receives permission for first import of Psilocybin
July 30, 2023
Commitments Received for GBP 0.7m
July 14, 2023
AMC Places Second Order of ArtemiC for US$1M
July 6, 2023
Malta Production Facility Receives EU-GMP Approval
May 1, 2023
Fundraise closed raising up to a total of GBP 2.09m
April 13, 2023
CannEpil now available by Named Patient Request in UK
April 11, 2023
Funding Commitments Received for GBP 1.8m
April 11, 2023
MGC Receive Permission for Psilocybin Research & Development
April 2, 2023
ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
March 20, 2023